A biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.
Switzerland
Joined March 2018
- Tweets305
- Following232
- Followers275
- Likes56
📢 NewCelX (Nasdaq: $NCEL) signed a binding term sheet for a proposed Mazindol divestiture: $500K upfront (cash/equity), up to $55M in potential milestones + 2–8% royalties.
Our focus remains NCEL-101 for #T1D.
🔗 finance.yahoo.com/healthcare…
💙 This #DiabetesAwarenessMonth, we're looking beyond managing #T1D.
NewCelX (Nasdaq: $NCEL) is developing NCEL-101, an investigational stem-cell-derived islet cell therapy, toward a potential functional cure for Type 1 Diabetes.
#CellTherapy #RegenerativeMedicine
🤖 Made with AI
At #EASD2026, Dr. @CamilloRicordi highlighted important hurdles in advancing #T1D therapies.
At NewCelX (Nasdaq: $NCEL), we are working to address two of them through NCEL-101 and our collaboration with Eledon Pharmaceuticals.
#Type1Diabetes #CellTherapy #Biotechnology
🤖 Made with AI
#StemCellAwarenessDay A global initiative to educate the public about stem cell research and regenerative medicine. At NewCelX ($NCEL), we're proud of CSO Prof. Michel Revel His stem-cell research helped lay the foundations for NCEL-101, our islet cell therapy for #T1D.
🤖 Made with AI
Thank you @BreakthroughT1D for bringing the #T1D research community together at #CRC2026.
Dr. Kfir Molakandov attended on behalf of NewCelX ($NCEL), connecting with leaders and collaborators as we advance NCEL-101 toward clinical translation.
#CellTherapy #Biotech
Tomorrow, NewCelX ($NCEL) will join @BreakthroughT1D Clinical & Research Congress in Philadelphia.
Dr. Kfir Molakandov will discuss NCEL-101, IND-enabling progress, and collaboration opportunities in #T1D cell therapy.
To connect: [email protected]
#CellTherapy #CRC2026
🤖 Made with AI
Why is NewCelX ($NCEL) heading to Philadelphia?
Because advancing #T1D cell therapy takes collaboration.
At @BreakthroughT1D Congress, we look forward to discussing NCEL-101, immune-protected islet replacement, and the path from lab to clinic.
#CellTherapy #CRC2026
Next week, NewCelX ($NCEL) will attend @BreakthroughT1D Clinical & Research Congress.
Dr. Kfir Molakandov, VP of R&D, will discuss NCEL-101, our stem cell-derived islet cell therapy for #T1D, and IND-enabling work toward clinical translation.
#CellTherapy #CRC2026
🤖 Made with AI
NewCelX ($NCEL) management will attend @BreakthroughT1D Clinical & Research Congress, Oct. 9–11, to discuss NCEL-101 and IND-enabling work toward a planned Phase 1/2a T1D trial.
finance.yahoo.com/healthcare…
@EledonPharma submitted an IND for tegoprubart in T1D islet transplantation.
Highly relevant to NewCelX ($NCEL): our NCEL-101 program is being developed with tegoprubart as part of an immune-protection strategy.
#T1D #CellTherapy #Biotech
Not every insulin-producing cell is the same.
A new @NatureRevEndo review asks how closely stem cell-derived beta cells match mature human beta cells.
For #T1D cell therapy, producing cells is only the beginning. Function matters.
nature.com/articles/s41574-0…
8.93B cells across 23 differentiations: a new UMass Chan update shows why scale matters in #T1D cell therapy.
NewCelX ($NCEL) is advancing NCEL-101 around 3 goals:
Produce. Purify. Protect.
#CellTherapy #Biotech
What if transplanted insulin-producing cells could be protected from immune attack while still working?
A new @Penn_State preclinical study highlights why immune protection matters in #T1D cell therapy. At NewCelX, that’s central to NCEL-101.
#CellTherapy #Biotech
For #T1D cell therapy, replacing lost beta cells is only part of the challenge.
At NewCelX ($NCEL), NCEL-101 is being advanced with immune protection central to the strategy, including our collaboration with @Eledon_Pharma.
#WorldImmunityMonth #CellTherapy #StemCells #Biotech
Recent T1D immunotherapy news shows how central immunity has become in #Type1Diabetes. @NICEComms
At NewCelX, NCEL-101 is focused on the next challenge: scalable islet cell replacement with immune protection built into the strategy.
#T1D #CellTherapy #StemCells #Biotech
At NewCelX, immune protection is central to our approach to #T1D cell therapy.
As #WorldImmunityMonth highlights the link between diabetes and immune biology, we are advancing NCEL-101 toward scalable islet cell replacement and a potential functional cure.
#health #Biotech
